Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427544 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00427544: Completed Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00427544 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427544, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonchildbearing potential, and to evaluate the effect of a high-fat meal on the PK and PD of PRA-027 administered to healthy women of nonchildbearing potential.
Interventions
- DRUG PRA-027
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
What the finished NCT00427544 record still lists
NCT00427544 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which PRA-027 is the first listed.
NCT00427544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427544 about?
NCT00427544 is a clinical study titled "Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential". The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonc...
What is the current status of trial NCT00427544?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-02. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00427544?
The interventions under investigation include: PRA-027 (DRUG).
Who is sponsoring clinical trial NCT00427544?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia